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Available online 18 September 2014Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage
disorder caused by deﬁciency of the enzyme iduronate-2-sulfatase
(IDS). The human IDS gene is located in chromosome Xq28. This is the
ﬁrst report of genotype and phenotype characterization of 49 Hunter
patients from 40 families of Argentina. Thirty different alleles have been
identiﬁed, and 57%were novel. The frequency of de novomutationswas
10%. Overall, the percentage of private mutations in our series was 75%.
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article under the CC BY-NC-ND license
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Mucopolysaccharidosis type II1. Introduction
Mucopolysaccharidosis type II (MPS II, Hunter disease, MIM 309900) is an X-linked lysosomal storage
disorder caused by deﬁciency of the enzyme iduronate-2-sulfatase (IDS). Clinical manifestations are coarse0), Argentina. Tel.: +54 221 4250497; fax: +54 221 4226947.
zenfeld).
evier Inc. This is an open access article under the CC BY-NC-ND license
/).
Table 1
List of mutations from 40 families of Argentinean Hunter patients. NA: sample not available.
Family Number of
patients
Type of mutation Genotype Protein alteration Exon Phenotype Presence of the mutation in
the mother
Reference
1 1 Complete IDS deletion Severe NA
2 1 Complete IDS deletion Severe NA
3 1 Complete IDS deletion Severe NA
4 1 Gene–pseudogene
recombination
Severe NA
5 1 Gene–pseudogene
recombination
Severe NA
6 1 Gene–pseudogene
recombination
Severe Y
7 2 Missense c.683C N A p.Pro228Gln 5 Severe Y This study
8 4 Missense c.1403G N A⁎ p.Arg468Gln 9 Severe Y This study, Whitley
et al. [7]
9 1 Missense c.253G N A⁎ p.Ala85Thr 3 Mild NA This study, Li et al. [8]
10 1 Missense c.1403G N A p.Arg468Gln 9 Severe N This study, Whitley
et al. [7]
11 1 Missense c.1403G N A + c.1394A N T p.Arg468Gln + p.Gln465Leu 9 Severe Y This study
12 1 Missense c.884A N T p.Lys295Ile 7 Severe Y This study
13 1 Missense c.181 T N C p.Ser61Pro 2 Mild Y This study, Sohn et al.
[9]
14 1 Missense c.998C N T p.Ser333Leu 7 Severe Y This study, Flomen
et al. [10]
15 1 Missense c.592G N A p.Asp198Asn 5 Severe N This study
16 1 Missense c.1033 T N A p.Trp345Arg 8 Severe NA This study
17 1 Missense c.425C N A p.Ser142Tyr 4 Severe Y This study
18 1 Missense c.401G N A⁎ p.Gly134Glu 3 Mild Y This study
19 2 Missense c.359C N A p.Pro120His 3 Severe Y This study, Hopwood
et al. [11]
20 1 Missense c.935G N A p.Gly312Asp 7 Mild Y This study
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Number of
patients
Type of mutation Genotype Protein alteration Exon Phenotype Presence of the mutation in
the mother
Reference
21 1 Missense c.641C N T p.Thr214Met 5 Severe NA This study
22 1 Missense c.253G N A p.Ala85Thr 3 Mild NA This study, Li et al. [8]
23 1 Missense c.1403G N A p.Arg468Gln 9 Severe NA This study, Whitley
et al. [7]
24 1 Missense c.1016 T N C p.Leu339Pro 8 Severe Y This study, Guo (2006)
25 1 Missense c.998C N T p.Ser333Leu 7 Severe Y This study, Flomen
et al. [10]
26 1 Missense c.469C N T p.Pro157Ser 4 Severe Y This study
27 1 Missense c.1433A N G p.Asp478Gly 9 Mild Y This study, Schröder
et al. [12]
28 Missense c.1393C N T p.Gln465X 9 Severe NA This study, Li et al. [13]
29 4 Nonsense c.820G N T p.Glu274X 6 Severe Y This study
30 1 Nonsense c.1327C N T p.Arg443X 9 Severe Y This study, Bunge et al.
[14]
31 1 Short deletion c.908_909delCT Frameshift 7 Severe Y This study
32 1 Short deletion c.411delT Frameshift 3 Severe Y This study
33 1 Short deletion c.22_37del16pb Frameshift 1 Severe N This study
34 2 Splicing c.508-1 g N a Partial exclusion exon 5 3′ de
IVS4
Mild Y This study
35 1 Splicing c.1122C N T G374G. Loss of 20 aa 8 Mild Y This study, Rathmann
et al. [15]
36 1 Splicing c.241-5a N t Exclusion of exon 3 3′ de
IVS2
Severe Y This study
37 1 Splicing c.708 + 1 g N a⁎ Exclusion exon 5 5′de
IVS5
Severe Y This study
38 1 Splicing c.1181-1 g N a Exclusion exon 9 3′ de
IVS8
Severe Y This study, Popowska
et al. [16]
39 1 Splicing c.1122C N T⁎ G374G. Loss of 20 aa 8 Mild Y This study, Rathmann
et al. [15]
40 2 Splicing c.1122C N T G374G. Loss of 20 aa 8 Mild Y This study, Rathmann
et al. [15]
⁎ The polymorphism c.438C N T was present.
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404 H. Amartino et al. / Molecular Genetics and Metabolism Reports 1 (2014) 401–406facial features, hepatosplenomegaly, dysostosis multiplex, heart disease, obstructive upper respiratory
disease, and frequent ear infections. Patients present a spectrum of phenotypes, ranging from severe to
attenuated course [1].
The human IDS gene is located in chromosome Xq28, spans approximately 24 kb and contains nine exons.
A full length cDNA clone of the gene showed an open reading frame of 1650 bp long predicting a proteinwith
550 aminoacids [2]. An IDS pseudogene (IDSP1) has been detected 20 kb distal to the telomeric side from the
functional gene, whose sequences are highly homologous to exons 2 and 3 and introns 2,3 and 7 of the IDS
gene [3]. To date, over 500 different mutations associated with MPS II have been identiﬁed [Human Gene
Mutation Database (HGMD); http://www.hgmd.org/].
We report the results of genotype and phenotype characterization of 49 Hunter patients of 40 families
from Argentina.
2. Materials and methods
2.1. Patients
Forty nine Hunter patients and their mothers (only 28 of mother samples where available) from 40
families were included in this study. Parents of the patients gave their informed consent previous to the
participation in the study. MPS II diagnosis was conﬁrmed by clinical examination and deﬁcient IDS activity
(activity of arilsulfatase B was normal in all cases, ruling out multiple sulfatase deﬁciency). Phenotype of
MPSII patients has been classiﬁed into attenuated (non-neuronopathic) or severe (neuronopathic) according
to the clinical evidence of cognitive or developmental involvement.
2.2. IDS genomic DNA analysis
Genomic DNA was extracted from EDTA blood using a QIAamp DNA Blood Mini kit (Qiagen, Valencia,
CA, USA). The 9 exons of the IDS gene including exon/intron boundaries were ampliﬁed by PCR using
speciﬁc primers as described [3]. Sequencing was carried out in both directions in a MegaBASE 1000
sequencer (Amersham Biosciences, Sunnyvale, CA, USA).
Recombination between IDS and IDSP1 leading to any inversion mutation was analyzed by a PCR
ampliﬁcation assay as described [4].
2.3. IDS cDNA analysis
Total cellular RNA was isolated from blood leukocytes by means of a total RNA isolation system
(Macherey Nagel, Duren, Germany). The isolated RNA samples were reverse transcribed using a speciﬁc
primer, according to the method of Jonsson [5] and then ampliﬁed in 2 overlapping fragments and
sequenced.
3. Results and discussion
Until now, we have found the mutation in all the patients analyzed from Argentina. Thirty different
MPS II alleles have been identiﬁed in a cohort of 49 Argentinean patients from 40 families: 18 missense
(60%), 5 splicing (17%), 3 short deletions (10%), 2 nonsense mutations (7%), 1 complex rearrangement
(a gene–pseudogene recombination leading to inversion) (3%) aswell as 1 gross gene deletion (3%) (Table 1).
We have not detected any insertions.
Of the mutations in this cohort, 17 out of 30 different alleles (57%) were novel (missense: p.Pro228Gln,
p.Lys295Ile, p.Asp198Asn, p.Trp345Arg, p.Ser142Tyr, p.Gly134Glu, p.Gly312Asp, p.Thr214Met, p.Gln465Leu,
p.Pro157Ser; splicing: c.508-1G N A, c.241-5A N T, c.708+ 1 g N a; nonsense: p.Glu274X; and short deletions:
c.908_909delCT, c.411delT, c.22_37del16pb).
The effect of novel missense mutations was analyzed by different means. They are all predicted to be
probably damaging, as analyzed by the prediction tool PolyPhen, and are localized in conserved
aminoacids between human and murine IDS but found in patients with both attenuated and severe
phenotypes. Glycines 134 and 312 are highly conserved among human sulfatases. Mutations found by us
405H. Amartino et al. / Molecular Genetics and Metabolism Reports 1 (2014) 401–406at these positions introduce negative charged aminoacids. Although the change in the structure of these
highly conserved aminoacids is high, both patients display an attenuated phenotype. The mutations
p.Pro228Gln and p.Pro157Ser in severe patients result from the replacement of a rigid nonpolar aminoacid
by a polar one. The rest of the novel missense mutations are not localized in conserved aminoacids,
however the effect in the phenotype is more devastating.
Previously described mutations detected by us were p.Arg468Gln, p.Ala85Thr, p.Ser333Leu, p.Pro120His,
p.Ser61Pro, p.Leu339Pro, p.Asp478Gly, p.Gln465X, p.Arg443X, the splice mutations c.1122C N T,
c.1181-1 g N a, and the recombination gene–pseudogene.
We found 3 novel splicing mutations. The mutation c.508-1 g N a was found in a patient with an
attenuated phenotype. At the molecular level, the mutation produced a predominant alternative transcript
and a minor quantity of the correct transcript. The mutant transcript results from the disruption of the 3′
original splice-site leading to the deletion of exon 5. The presence of the correct mRNA, although in minor
quantity, would explain the less severe clinical manifestations observed in this patient. On the other side,
the splicing mutations c.241-5a N t and c.708 + 1 g N a, each generate a unique mRNA product, whose
sequence corresponds to the complete deletion of exons 3 and 5, respectively, and are associated with a
severe phenotype.
In one patient, two different “neighbor” mutations (p.Arg468Gln + p.Gln465Leu) were found. The
mother was a carrier of both mutations, but not the grandmother and the 4 maternal aunts. Few other
reports described the presence of “neighbor” mutations [6]. The ﬁnding of these two close mutations in
the patient and his mother but not in the grandmother suggests that they are de novo mutations in a
mutation-prone region and reinforces the idea that they arose simultaneously.
Three patients had a complete gene deletion. None of the ﬂanking markers tested were detected,
suggesting that the deletion spans more than 20 kb upstream and 7 kb downstream of the IDS locus, and
includes the IDSP1 locus. No atypical symptoms of Hunter syndrome were found in these patients,
indicating that the deletion did not compromise contiguous genes. The phenotype of these patients is the
severe form of the disease. The same phenotype was observed for the three of the patients who exhibited a
recombination between gene and pseudogene.
The absence of the probands' mutations in their mother suggests that in the three cases, the
mutations occurred de novo (10%). However, the possibility of germinal mosaicism could not be ruled
out. The theoretical rate calculated by the Bayesian methods for this condition would be 33%, so the
value found in our cohort is much less. In the cohort reviewed by Froissart et al., they found values of
de novo mutations close to the expected in any X chromosomal disease in which male reproductive
ﬁtness is extremely low [2]. The low value found in our group could be because much of the patients
from Argentina were diagnosed because of a previous family history of MPS II, meaning there are still
many undiagnosed patients in Argentina. We also found a low rate of the polymorphism in exon
4 c.438C N T, only in 4 families (10%) as compared to the frequency reported in normal controls of
around 30% [3].
The percentage of private mutations in our series was 75%, a high proportion as usually seen in other
series.
Although genotype–phenotype correlation is difﬁcult to establish, it is worth mentioning that
both missense (p.Ser61Pro, p.Ala85Thr, p.Gly134Glu, p.Gly312Asp, p.Asp478Gly) and splice mutations
(c.1122C N T, c.508-1G N A) were associated with non-neuronopathic (“attenuated”) phenotype. From our
series of 30 alleles, 7 (23%) were found associated with mild forms. Three of the mutations associated with
the non-neurological phenotype, are new (c.508-1 g N a, p.Gly134Glu, p.Gly312Asp).
This is the ﬁrst report of mutations of Hunter patients from Argentina. Our results provide further
evidence of mutational heterogeneity of the IDS gene observed in patients with MPS II.Role of the funding source
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